A positive structural finding should not erase a neutral functional result. This 2006 rat study reported a mixed pattern after experimental myocardial infarction. Primary study
The experiment and results
Coronary occlusion produced myocardial injury, and Semax was administered early after the procedure. At 28 days, the authors described less cardiomyocyte hypertrophy, a more favorable relationship between contractile and mitochondrial structures, and partial attenuation of elevated left ventricular end-diastolic pressure. They also stated that cardiac work was not affected. Primary report
Our appraisal: structure, pressure, and performance differ
Cardiac remodeling is a broad term. Cell size, ultrastructure, filling pressure, and pump performance are related but noninterchangeable measurements. A headline claiming complete functional recovery would go beyond a report that explicitly retains an unchanged cardiac-work outcome.
Ultrastructural observations can suggest altered cellular organization. They do not directly quantify total energy production, exercise capacity, or survival. A proposed explanation involving mitochondrial support needs appropriate functional tests before becoming an established mechanism.
The intervention timing is another important boundary. Early administration after an experimentally created injury does not establish reversal of long-standing human heart failure. A later observation of the outcome is not the same as late initiation of treatment.
The model also fixes an injury mechanism and study environment. Human infarction care involves different timing, comorbidities, and accompanying treatments. Translation requires more than matching the disease name.
This English-abstract-bounded record supports further examination of selected remodeling endpoints. It does not show that Semax improves every aspect of cardiac function, prevents clinical heart failure, or substitutes for established infarction care. Full review should assess injury severity, survival and exclusions before the final measurement, allocation, blinded tissue assessment, and all reported functional outcomes. Keeping the neutral result visible is central to an accurate summary.
Frequently asked questions
Was this an animal infarction model?
Yes.
Was treatment initiated late in chronic heart failure?
No; administration began early after the experimental injury.
Were selected remodeling measures favorable?
The authors reported that pattern.
Did cardiac work improve?
The abstract states it was not affected.
Is mitochondrial appearance a direct exercise-capacity measurement?
No.
Does a 28-day endpoint mean treatment started at day 28?
No.
What should remain visible in the conclusion?
Both the favorable structural findings and the neutral functional result.